Skip to main content
. 2017 Aug 7;8(52):89566–89579. doi: 10.18632/oncotarget.20023

Figure 2.

Figure 2

A. IC50 survival curves for AML-derived cell lines treated with HXR9 or CXR9. B. Proliferation of primary AML cells treated with varying concentrations of HXR9 or CXR9. Each value is the mean of 3 independent repeats, error bars show the SEM.